Allyson Munch
Family Medicine · Hannibal, MONPI 1528682630
Payments from drug & device makers
Across 110 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$384
- Amgen$287
- AstraZeneca$156
- Pfizer$106
- Novo Nordisk$104
- GSK$101
- plus $732 from 20 others
What the payments were for
- Food & beverage$1,871100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $384 |
| Amgen | 17 | $287 |
| AstraZeneca | 9 | $156 |
| Pfizer | 5 | $106 |
| Novo Nordisk | 6 | $104 |
| GSK | 6 | $101 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $100 |
| Merck | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Lilly USA, LLC | 2 | $43 |
| Acadia Pharmaceuticals Inc | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Sanofi | 1 | $38 |
| Verona Pharma, Inc. | 2 | $36 |
| Globus Medical | 1 | $24 |
| Novartis | 1 | $23 |
| Alkermes, Inc. | 1 | $23 |
| Exact Sciences | 1 | $23 |
| Medtronic | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Resmed Corp | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$1,871 in reported general payments places this provider in the 70th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $16,919 |
| Modafinil | 12 | $8,766 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,753 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,738 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $1,657 |
| Hydroxychloroquine Sulfate | 24 | $990 |
| Olanzapine | 24 | $742 |
| Gabapentin | 60 | $672 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $629 |
| Omeprazole | 29 | $591 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $407 |
| Amitriptyline Hcl | 13 | $360 |
| Celecoxib | 13 | $349 |
| Pregabalin | 14 | $344 |
| Atorvastatin Calcium | 58 | $343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $106 | $16,91921 claims |
| GSKAnoro Ellipta | $101 | $6,75314 claims |
| AstraZenecaSymbicort | $156 | $3,73817 claims |
| Lilly USA, LLCOlanzapine | $43 | $74224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Hannibal
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.